Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382528 | 0.95 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL6384570 | 0.94 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL31158519 | 0.84 | MAPK1 (0.39) | ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL6383925 | 0.82 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL6381321 | 0.81 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL6381885 | 0.76 | HTT (0.39) | ALDH1A1SMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL3387081 | 0.76 | MAPT (0.40) | ALDH1A1SMN1; SMN2L3MBTL1PTGS1PTGS2 | |
| SCHEMBL28480405 | 0.73 | — | — | |
| SCHEMBL29777610 | 0.73 | KDM4E (0.35) | ALDH1A1L3MBTL1 | |
| SCHEMBL6380642 | 0.73 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4709711-A1 | ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | Beone Medicines I GmbH (CH) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024230803-A1 | ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | BEIGENE, LTD. (GB) | 2024-11-14 | — | — | WO | disclosed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | ALDH1A1 720/4885SMN1; SMN2 2441/4885HPGD 83/4885 |
| US-20260125346-A1 | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | NR3C1, NR3C2, PIK3R4 | ALDH1A1 1598/4885SMN1; SMN2 1452/4885HPGD 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.